COHANCE LIFESCIENCES LTD Stock Price Today (NSE: COHANCE)
Fundamental Score
COHANCE LIFESCIENCES LTD Share Price — Live NSE/BSE Price, Fundamentals & Analysis
COHANCE LIFESCIENCES LTD share price today is ₹428.90, down 0.12% on NSE/BSE as of 19 June 2026. COHANCE LIFESCIENCES LTD (COHANCE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹21.15K (Cr). The 52-week high for COHANCE share price is ₹1121.15 and the 52-week low is ₹266.70. At a P/E ratio of 61.57x, COHANCE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.67% and a debt-to-equity ratio of 0.12.
COHANCE LIFESCIENCES LTD Share Price Chart — NSE/BSE Historical Performance
COHANCE LIFESCIENCES LTD share price chart: -0.78% return over the past month. 52-week high ₹1121.15, 52-week low ₹266.70.
COHANCE LIFESCIENCES LTD — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹428.45 | ₹430.55 | ₹424.10 | ₹428.90 | 2.80L (Cr) | |
| ₹431.05 | ₹444.30 | ₹427.10 | ₹429.40 | 7.74L (Cr) | |
| ₹427.30 | ₹435.00 | ₹427.20 | ₹431.50 | 6.09L (Cr) | |
| ₹428.75 | ₹428.75 | ₹428.75 | ₹428.75 | 0.00 (Cr) | |
| ₹434.90 | ₹437.80 | ₹427.45 | ₹428.75 | 3.28L (Cr) | |
| ₹436.00 | ₹444.75 | ₹431.85 | ₹434.90 | 6.60L (Cr) | |
| ₹422.00 | ₹440.00 | ₹422.00 | ₹434.85 | 14.31L (Cr) | |
| ₹424.00 | ₹424.00 | ₹416.60 | ₹418.55 | 4.61L (Cr) | |
| ₹424.20 | ₹429.20 | ₹417.35 | ₹419.90 | 7.03L (Cr) | |
| ₹427.80 | ₹428.95 | ₹415.15 | ₹420.15 | 11.69L (Cr) |
COHANCE LIFESCIENCES LTD — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹431.05 | ₹444.30 | ₹424.10 | ₹428.90 | -0.50% | |
| ₹487.00 | ₹505.00 | ₹391.05 | ₹431.50 | -11.40% | |
| ₹308.95 | ₹514.90 | ₹292.50 | ₹483.25 | +56.42% | |
| ₹295.00 | ₹312.90 | ₹266.70 | ₹301.45 | +2.19% | |
| ₹369.90 | ₹399.45 | ₹303.05 | ₹309.95 | -16.21% | |
| ₹528.95 | ₹531.35 | ₹368.40 | ₹381.30 | -27.91% | |
| ₹570.05 | ₹572.00 | ₹518.15 | ₹528.60 | -7.27% | |
| ₹753.40 | ₹760.80 | ₹556.35 | ₹564.40 | -25.09% | |
| ₹883.45 | ₹917.85 | ₹749.05 | ₹753.40 | -14.72% | |
| ₹876.80 | ₹1038.90 | ₹857.05 | ₹879.10 | +0.26% | |
| ₹989.00 | ₹999.65 | ₹856.30 | ₹880.60 | -10.96% | |
| ₹964.00 | ₹1121.15 | ₹936.00 | ₹998.45 | +3.57% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Cohance is a high-risk, high-reward CDMO play dependent on complex chemistry execution and M&A speculation, overshadowed by FDA concerns and weak financials.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Cohance Lifesciences saw a 19.27% surge on April 10, hitting an upper circuit of , driven by a 15-fold volume explosion. The trigger was the appointment of Mr. Sisir K. Mishra as Company Secretary, Compliance Officer, and Key Managerial Personnel. The market interprets this as a signal for a potential capital event, though the company hasn't confirmed any deal.
CORE STORY (THE REAL GAME)
Cohance is a CDMO play betting on complex generics, biosimilars, and high-growth modalities like Antibody-Drug Conjugates (ADCs) and Oligonucleotides to move up the value chain. It's a high-risk, high-reward pivot from commoditized generics, complicated by recent FDA warning letters.
- M&A speculation after key hire
- Technical bounce from 52-week low
- Strategic investments in growth areas
- Successful remediation of FDA warning letter
- Announcement of a strategic M&A transaction
- Strong earnings growth in ADC and Oligonucleotide segments
- 100% promoter pledging
- FDA warning letter for Hyderabad facility
- Q3 FY26 net profit down 74% YoY
- Significant promoter stake sale in Sept 2025
- High P/E of 61.57x vs industry P/E of 31.77x
Promoter holding decreased by 8.92%, FII decreased by 0.72%, DII increased by 9.41%
Indian pharma exports are growing, projected to reach $130 billion by 2030, but face global pricing pressures.
Yes - Free Cash Flow 5Y: ₹1137.04 Cr
Next 3-6 months hinge on FDA remediation, Q4 results, and any M&A news. Key is whether Cohance can demonstrate execution in complex modalities.
Primary Thesis Risk
Failure to resolve FDA issues and execute the complex chemistry strategy will lead to significant downside.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
COHANCE LIFESCIENCES LTD Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
COHANCE LIFESCIENCES LTD Fundamental Analysis & Valuation Benchmarking
Educational evaluation of COHANCE across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (40.21%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Conservative Debt Levels (D/E: 0.12)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.48x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1137.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (57.49%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 27.32%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
7 factors identified
Premium Valuation Risk (P/E: 61.57x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-46.50%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-7.98%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-5.33% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-5.33% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
High Share Pledging Risk (100.00%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
COHANCE LIFESCIENCES LTD vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare COHANCE LIFESCIENCES LTD with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
COHANCE LIFESCIENCES LTDCOHANCE LIFESCI...Selected✓ COHANCE • 543064 | 10.4/100 | ₹428.90₹429 | ₹21150.19₹21150.19 | 61.57Average 61.6 Average | 12.67%Average 12.67% Average | 14.89%Average 14.89% Average | 0.12Excellent 0.1 Excellent | -5.33%Poor -5.33% Poor | 7.51%Good 7.51% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
COHANCE LIFESCIENCES LTD PE Ratio History
Historical price-to-earnings ratio for COHANCE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹10.45 | ₹528.60 | 50.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
COHANCE LIFESCIENCES LTD Dividend History
Annual cash dividends paid by COHANCE — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹203.65 Cr |
| FY 2022 | ₹101.83 Cr |
| FY 2021 | ₹25.46 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
COHANCE LIFESCIENCES LTD Quarterly Performance
Latest quarterly metrics for COHANCE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-7.98%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-46.50%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.51%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-5.33%
Compounded annual net profit growth over 5 years
COHANCE LIFESCIENCES LTD Technical Indicators
SMA 50, SMA 200, RSI and volume signals for COHANCE — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
COHANCE LIFESCIENCES LTD Financial Statements
Annual income statement, balance sheet and cash flow for COHANCE LIFESCIENCES LTD (COHANCE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for COHANCE LIFESCIENCES LTD
About COHANCE (COHANCE LIFESCIENCES LTD)
COHANCE LIFESCIENCES LTD is a dynamic pharmaceutical innovator, focused on the intricate dance between scientific discovery and efficient production. It navigates the complexities ...of drug development, specializing in the creation of building blocks for tomorrow's therapies. From initial research to large-scale manufacturing, the company is committed to precision and quality, serving as a trusted partner for pharmaceutical companies across the globe. COHANCE blends cutting-edge research with practical manufacturing expertise, playing a pivotal role in the intricate pharmaceutical supply chain. Its mission is to fuel advancements in healthcare by enabling the streamlined development and manufacturing of critical pharmaceutical components. COHANCE concentrates on the vital components that make medicines work, focusing on the development and manufacture of specialized chemical compounds. The company excels in the creation of Active Pharmaceutical Ingredients (APIs), the very heart of medications, along with advanced intermediates that serve as the stepping stones in their synthesis. COHANCE also manufactures specialty chemicals crucial for drug development, as well as formulated drugs that have proven their efficacy and are widely prescribed. By concentrating on core pharmaceutical elements, COHANCE empowers its clients to focus on innovation and distribution, confident in the quality and reliability of their source materials. COHANCE LIFESCIENCES LTD extends its reach beyond geographical boundaries, providing its specialized services and products to pharmaceutical companies in India, the United States, Europe, and other countries. COHANCE enables the quick and efficient development of life-saving pharmaceuticals by utilizing its worldwide network and state-of-the-art facilities. With a focus on quality control and regulatory compliance, COHANCE assures its clients that its products meet the highest standards. COHANCE is dedicated to advancing healthcare worldwide by providing vital components for the pharmaceutical sector with accuracy and dependability, from APIs and sophisticated intermediates to formulated drugs.
Company Details
Key Leadership
Corporate Events
COHANCE Share Price: Frequently Asked Questions
What is the current share price of COHANCE LIFESCIENCES LTD?
COHANCE LIFESCIENCES LTD (COHANCE) trades at ₹428.90 on NSE and BSE. Market cap ₹21.15K (Cr). Educational data only.
What is the P/E ratio of COHANCE LIFESCIENCES LTD?
COHANCE LIFESCIENCES LTD has a P/E of 61.57x vs industry average 31.77x.
What is the Bull Run score for COHANCE LIFESCIENCES LTD?
COHANCE LIFESCIENCES LTD has a Bull Run score of 10.4/100 based on 25+ financial parameters.
Does COHANCE LIFESCIENCES LTD pay dividends?
COHANCE LIFESCIENCES LTD has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of COHANCE LIFESCIENCES LTD?
COHANCE LIFESCIENCES LTD has ROE of 12.67%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of COHANCE LIFESCIENCES LTD?
COHANCE LIFESCIENCES LTD has debt-to-equity of 0.12.
Is COHANCE LIFESCIENCES LTD a good investment?
Bull Run gives COHANCE LIFESCIENCES LTD a score of 10.4/100. This is not investment advice — consult a SEBI-registered advisor.